title: Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
abstract: Iron chelators are increasingly combined clinically but the optimal conditions for cellular iron mobilization and mechanisms of interaction are unclear. Speciation plots for iron(III) binding of paired combinations of the licensed iron chelators desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) suggest conditions under which chelators can combine as 'shuttle' and 'sink' molecules but this approach does not consider their relative access and interaction with cellular iron pools. To address this issue, a sensitive ferrozine-based detection system for intracellular iron removal from the human hepatocyte cell line (HuH-7) was developed. Antagonism, synergism or additivity with paired chelator combinations was distinguished using mathematical isobologram analysis over clinically relevant chelator concentrations. All combinations showed synergistic iron mobilization at 8 h with clinically achievable concentrations of sink and shuttle chelators. Greatest synergism was achieved by combining DFP with DFX, where about 60% of mobilized iron was attributable to synergistic interaction. These findings predict that the DFX dose required for a half-maximum effect can be reduced by 3·8-fold when only 1 μmol/l DFP is added. Mechanisms for the synergy are suggested by consideration of the iron-chelate speciation plots together with the size, charge and lipid solubilities for each chelator. Hydroxypyridinones with low lipid solubilities but otherwise similar properties to DFP were used to interrogate the mechanistic interactions of chelator pairs. These studies confirm that synergistic cellular iron mobilization requires one chelator to have the physicochemical properties to enter cells, chelate intracellular iron and subsequently donate iron to a second 'sink' chelator.
authors.affiliation: Department of Haematology, University College London, London, UK.
authors.forename: Evangelia
authors.initials: E
authors.lastname: Vlachodimitropoulou Koumoutsea
authors.affiliation: Department of Haematology, University College London, London, UK.
authors.forename: Maciej
authors.initials: M
authors.lastname: Garbowski
authors.affiliation: Department of Haematology, University College London, London, UK.
authors.forename: John
authors.initials: J
authors.lastname: Porter
mesh_terms: D001565:Benzoates / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D002460:Cell Line; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D042541:Intracellular Space / Q000378:metabolism; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011728:Pyridones / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D014230:Triazoles / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; C098211:1-(ethan-1-ol)-2-methyl-3-hydroxypyridin-4-one; D007501:Iron; D003676:Deferoxamine; D000077588:Deferasirox
keywords: combination chelation therapy; iron chelation; iron overload; isobologram; thalassaemia